SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as former President Trump's renewed threats of tariffs on NATO allies, particularly over the acquisition of Greenland, spark fears of a trade war with Europe. This escalating geopolitical tension is causing widespread market jitters and calls for caution, though many investors are also discussing it as a potential "buy the dip" opportunity for growth stocks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amidst a broader software sector selloff, with community discussion centered on whether AI advancements pose a threat or opportunity. Recent news of a key OpenAI partnership and the strategic acquisition of cybersecurity firm Armis, alongside positive analyst reiterations, fuels debate over the stock's oversold status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why SciSparc Stock Is Gaining Today

SciSparc shares are surging after it moved to acquire MUSE endoscopy IP, broadening beyond neuroscience into GERD device commercialization.read more...

<ul class="summary-bullets"><li>The company said it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device.</li><li>The number of shares issued to Xylo would be 19.99% of the issued and outstanding share capital of SciSparc as of the closing date of the transaction, SciSparc said.&nbsp;</li><li>Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion instead of issuing shares, it added.</li></ul> SciSparc Ltd. (SPRC) on Wednesday said that its majority-owned unit, NeuroThera Labs Inc., signed a binding term sheet to acquire a treasury of patents, trademarks, and intellectual property rights for innovative endoscopic systems and medical cameras from Xylo Technologies Ltd.Shares of the company jumped as much as 34% in the pre-market session at the time of writing.<h2 class="st-heading-2">About The Rights And Patents</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3195068/0/en/SciSparc-to-Acquire-Treasury-of-Patents-for-Innovative-Medical-Endoscopy-Systems.html">said</a> it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device designed for a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). According to SciSparc, the GERD device market is projected to reach $3.03 billion by 2030 from about $2.5 billion in 2024.In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. The number of shares issued would be 19.99% of SciSparc's issued and outstanding share capital as of the transaction's closing date, the company said.Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion, rather than issuing shares. However, this is subject to negotiation and the signing of definitive acquisition agreements, the company added.<h2 class="st-heading-2">What Does SciSparc Intend To Do?</h2>Xylo had entered a licensing and distribution agreement with a Shanghai-based medical instruments company in 2019 for commercialization in Greater China.SciSparc now intends to replicate this model across territories such as North America, Europe and Latin America by pursuing exclusive partnerships with regional distributors to accelerate worldwide commercialization.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.SPRC stock is down by 68% this year and by about 49% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 

Equity

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 


SciSparc (SPRC) announced on Monday that it has decided to terminate the proposed merger with AutoMax Motors.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161557/0/en/SciSparc-Ltd-Announces-Framework-Agreement-Regarding-Merger-with-AutoMax-Motors.html">announced</a> that the decision was mutual, and the merger agreement is null, effective immediately. The two companies also established clear repayment terms for SciSparc’s existing loans to AutoMax, totaling a principal amount of $6.25 million. The companies did not provide a reason for scrapping the proposed merger.SPRC shares traded 2% higher at the time of writing. Scisparc stated that AutoMax will repay $4.25 million in principal, with interest, in a single lump sum payment on Jan. 1, 2028, and another $2 million in principal, with interest, in monthly installments starting Nov. 20, 2025. All accrued interest will be paid at the outset, the company added.Late in August, the pharmaceutical company said that its shareholders approved its proposed merger with AutoMax, a parallel vehicle importer in Israel. The two companies entered into a definitive agreement in April 2024, under which SciSparc would acquire 100% of AutoMax’s share capital by way of a reverse merger between SciSparc Merger Sub, a wholly owned subsidiary of the company, and AutoMax, with AutoMax continuing as a wholly owned subsidiary of SciSparc. The proposed merger was aimed at diversifying SciSparc’s portfolio and capitalizing on the expanding electric vehicle market in Israel.SciSparc is currently focused on a portfolio based on cannabinoid pharmaceuticals. It is developing drugs for the treatment of Tourette Syndrome, Alzheimer’s disease, and Autistic Spectrum Disorders (ASD), among others.&nbsp;SPRC stock is down 37% this year but is up approximately 3% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SciSparc And AutoMax Motors Scrap Proposed Merger

The decision was mutual, and the merger agreement is null, effective immediately, SciSparc said.

SciSparc’s (SPRC) shares soared over 61% on Thursday after the company announced its plans to launch an initiative to advance 3D protein modeling using quantum computing technology.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156166/0/en/SciSparc-Resolves-to-Launch-Innovative-Quantum-Computing-Enabled-3D-Protein-Modeling-Initiative-to-Revolutionize-AI-Drug-Discovery.html">will</a> form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling to create new intellectual property. Initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions, with the goal of targeting applications in drug discovery for neurological and rare diseases. SciSparc also said that it expects to incorporate a new wholly owned Israeli subsidiary, which will operate the initiative.The firm explained that knowing a protein’s three-dimensional structure is key to understanding how it interacts in the body and how to design effective drugs. Scientists typically use computers to predict the 3D structure. However, the process has its challenges, including the dynamic nature of proteins, which involves constantly shifting between different conformations, SciSparc said.Quantum computing may simulate the energy dynamics of proteins with greater precision, capturing their complex movements and interactions with potential drugs with much higher accuracy, the company said. The firm expressed optimism that this may pave the way for breakthroughs in structural biology and personalized medicine.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_12_19_35_PM_png_a67dccb366.webp" alt="SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="64"><figcaption>SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to hit $10 by the end of the day.<stembedurl>https://stocktwits.com/Proecadguy/message/629996574</stembedurl>Late last month, the company said that its shareholders approved its proposed merger with AutoMax Motors, a parallel vehicle importer in Israel. Following the closing of the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company’s share capital. However, the merger's closing is subject to approval by the Israeli court.SPRC stock is down approximately 19% this year and up about 18% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SciSparc Stock Soared 61% Today – Here’s An Important Update

The company will establish a dedicated research team to integrate quantum computing algorithms into 3D protein modeling, aiming to create new intellectual property.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SPRC
Scisparc Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest SPRC News

SPRCScisparc Ltd